Trastuzumab therapy vs tetracycline controlled ERBB2 downregulation: influence on tumour development in an ERBB2-dependent mouse tumour model

Trastuzumab (Herceptin) has improved therapy of breast cancer. Only patients overexpressing ERBB2 are treated with trastuzumab, whereas its use in tumours without ERBB2 expression is useless. This led to the concept that the subgroup of trastuzumab-sensitive tumours is ‘ERBB2-dependent’, meaning tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Hermes, M, Schormann, W, Brulport, M, Uhlemann, K, Lupatsch, F, Horn, L C, Schumann, A, Allgaier, C, Weishaupt, M, Engeland, K, Müller, G A, Mössner, J, Bauer, A, Schiffer, I B, Gebhard, S, Schmidt, M, Lausch, E, Prawitt, D, Wilhelm, C, Hengstler, J G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2008
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2391101/
https://www.ncbi.nlm.nih.gov/pubmed/18454161
http://dx.doi.org/10.1038/sj.bjc.6604318

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2391101/
https://www.ncbi.nlm.nih.gov/pubmed/18454161
http://dx.doi.org/10.1038/sj.bjc.6604318

Ejemplares similares